Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature.
Cutis
; 104(3): E11-E15, 2019 Sep.
Article
en En
| MEDLINE
| ID: mdl-31675404
ABSTRACT
The expanding use of novel targeted anticancer agents such as sorafenib has led to an increasing number of dermatologic adverse events. Although cutaneous adverse events are commonly described in patients taking sorafenib, there are few reports describing psoriasis secondary to this medication. In this report, we describe 3 patients with sorafenib-induced psoriasiform drug eruption and review the available literature of similar patient cases. Our findings highlight shared characteristics among affected patients and potential treatment options for patients in whom sorafenib cannot be discontinued. Increased awareness of such drug eruptions and management options is critical to prevent suboptimal dosing and decreased quality of life.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Erupciones por Medicamentos
/
Carcinoma Hepatocelular
/
Sorafenib
/
Neoplasias Hepáticas
/
Antineoplásicos
Tipo de estudio:
Etiology_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Cutis
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos